Drugs / IC19/1563
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04892277 | Oct 2022 → Mar 2028 expected | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IC19/1563 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04892277 ↗ |
| Target | CD19 | “in-house, point of care manufactured autologous anti-CD19 CAR-expressing T-lymphocytes IC19/1563” NCT04892277 ↗ |